文献速递神经肿瘤

卡麦角林对无功能垂体腺瘤术后肿瘤残留的影响

Effect of cabergoline on tumor remnant after surgery in nonfunctioning pituitary adenoma.
PubMed 文献 · J Neurooncol · 2022-11-10

本研究为回顾性多中心研究,分析无功能垂体腺瘤术后肿瘤残留患者使用卡麦角林(CAB)的效果,共纳入62例术后残留患者,其中22例接受CAB治疗,40例观察。CAB组与观察组肿瘤残留最大直径均无显著变化,两组肿瘤反应类型无统计学显著差异,但CAB组部分缓解比例较高、进展比例较低。

要点

  • CAB组肿瘤残留最大直径治疗前后无显著变化(11.5 mm vs 12.0 mm,p=0.85)。
  • 观察组肿瘤残留最大直径随访前后无显著变化(8.5 mm vs 9.0 mm,p=0.064)。
  • CAB组90.9%患者无进展(稳定17例、部分缓解3例),观察组85%无进展。

核心结论

  • CAB组与观察组肿瘤反应类型无显著差异,但CAB组部分缓解比例较高、进展比例较低,不能排除CAB对术后肿瘤残留的潜在治疗获益。

研究设计与样本

  • 回顾性多中心研究,纳入142例接受手术的无功能垂体腺瘤患者,选取62例术后肿瘤残留患者,其中22例接受卡麦角林治疗(CAB组),40例接受主动监测(观察组)。

主要发现

  • CAB组肿瘤残留最大直径治疗前11.5(6.0-16.9)mm vs 治疗结束时12.0(7.0-15.0)mm,p=0.85,无显著变化。
  • 观察组肿瘤残留最大直径随访前8.5(6.0-13.7)mm vs 随访结束时9.0(6.2-14.0)mm,p=0.064,无显著变化。
  • 随访时间CAB组13(10.5-17)个月 vs 观察组77.5(50.2-107.2)个月,p<0.001。
  • CAB组肿瘤反应:稳定疾病17/22(77.2%)、部分缓解3/22(13.6%)、进展2/22(9.1%);观察组:稳定疾病32/40(80%)、部分缓解2/40(5%)、进展6/40(15%),两组比较p=0.42。
  • 观察组进展比例是CAB组的1.65倍,CAB组部分缓解比例是观察组的2.72倍。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • CAB组随访时间显著短于观察组(13个月 vs 77.5个月,p<0.001)。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: In recent years, dopamine agonists (DAs) have become an attractive therapeutic option to prevent both tumor growth and post-surgical tumor remnant growth in clinically non-functioning pituitary adenoma (NFPA). AIM: To analyze our experience on the effect of cabergoline (CAB) on tumor remnant after initial surgery in NFPA patients. PATIENTS AND METHODS: A retrospective and multicenter study of NFPA patients with tumor remnant after surgery treated with CAB was performed. RESULTS: From a total of 142 NFPA patients (79 men, 55.2%; mean age 57.2 ± 14.2 year) who underwent surgery, we selected 62/142 (43.7%) patients (32 men, 51.6%; mean age 59.3 ± 13.9 year) with tumor persistence (TP) after surgery. In 22/62 (35.5%) TP patients CAB was used (CAB group), while the rest of the patients (40/62, 64.5%) underwent active surveillance [observation (OBS) group)]. The maximum diameter of the tumor remnant did not change significantly in either the CAB group [11.5 (6.0-16.9) mm vs. 12.0 (7.0-15.0) mm, p = 0.85) or the OBS group [8.5 (6.0-13.7) mm vs. 9.0 (6.2-14.0) mm, p = 0.064) at the end of the follow-up [13 (10.5-17) vs. 77.5 (50.2-107.2) months, CAB vs. OBS group; p < 0.001]. At the end of the treatment period with CAB most of the patients (n = 20/22, 90.9%) showed no progression of the tumor remnant [stable disease, SD (n = 17/22, 77.2%) and partial response, PR (n = 3/22, 13.6%)], while 2/22 patients (9.1%) exhibited progression. Similar response rates were observed in the OBS group [SD (n = 32/40, 80%), PR (n = 2/40, 5%), and progression (n = 6/40, 15%)]. Although no statistically significant differences (p = 0.42) were found in these responses, the percentage of progression was 1.65 times higher in the OBS group compared to the CAB group. On the contrary, the percentage of PR was 2.72 times higher in the CAB group compared to the OBS group, despite a significantly shorter follow-up period in the CAB group. CONCLUSION: Although the present study showed no significant differences in the type of tumor response between the CAB and OBS groups of patients, the percentage of PR was higher and that of progression lower in the CAB group compared to the OBS group. This finding does not rule out a potential therapeutic benefit of CAB in the management of tumor remnant in patients with NFPA undergoing surgery.

来源:J Neurooncol,查看原文。版权归原作者所有。

引用

  1. Iglesias P, Biagetti B, Araujo-Castro M, et al. Effect of cabergoline on tumor remnant after surgery in nonfunctioning pituitary adenoma. J Neurooncol. 2022. PMID: 36355257. doi:10.1007/s11060-022-04149-7

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。